Image For Activity Cover
The Future of IV Platelet Inhibition in the Catheterization Laboratory
Overview

Suzanne J. Baron, MD, FSCAI

Moderator

Srihari S. Naidu, MD, FSCAI

Moderator

Sandeep Nathan, MD, FSCAI

Speaker

Mitul Patel, MD, FSCAI

Speaker

Jennifer A. Rymer, MD, MBA, MHS

Speaker

Maya Serhal, MD, FSCAI

Speaker



Welcoming Remarks and CME Information, Suzanne J. Baron, MD, FSCAI

Cangrelor - The Data Behind When and Why to Use IV Anti-Platelet Therapy in the Catheterization Laboratory, Jennifer A. Rymer, MD, MBA, MHS

What’s Clot Got to Do With It? Techniques for Managing Heavy Thrombus Burden, Mitul Patel, MD, FSCAI

Case Presentation of Cardiac Arrest (or Shock or STEMI), Sandeep Nathan, MD, FSCAI

Case Presentation of Complex PCI (CTO vs. MVD vs. LMCA), Maya Serhal, MD, FSCAI

Acknowledgment of Commercial Support ​

This activity is supported by an unrestricted educational grant from Chiesi.

Learning Objectives

Upon completion of this activity, participants will be able to:

1. Review the literature supporting the use of IV P2Y12 Inhibitor therapy.

2. Utilize intravenous pharmacotherapy in treating high clot burden in the catheterization laboratory.

3. Discuss real-world cases presentations involving the use of IV P2Y12 Inhibitor therapy.

Disclosures

PLANNER

Suzanne Baron: No financial relationships with ineligible companies.


FACULTY

Suzanne Baron, Jennifer Rymer, and Maya Serhal: No financial relationships with ineligible companies.

Srihari S. Naidu: BMS - Advisory Board, Consulting, PI; Cytokinetics - Advisory Board, Consulting, PI; Zoll Therox - Advisory Board, Consulting, PI; Tenaya - Advisory Board.

Sandeep Nathan: Getinge - Consulting; Medtronic - Consulting; Merit Medical - Consulting; Terumo - Consulting; Zoll - Consulting.
​​

Mitul Patel: Bolt Medical - Stocks, Consulting; Boston Scientific Corp. - Consulting; Medtronic - Consulting.


REVIEWER

Binita Shah: No financial relationships with ineligible companies.


SCAI STAFF

Laura Porter: No financial relationships with ineligible companies 

Continuing Education Information

Accreditation Statement
The Society for Cardiovascular Angiography and Interventions (SCAI) is accredited by the 
Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

​Credit Designation
SCAI designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

​ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Successful Completion
Watch the content and complete the evaluation to obtain credit.

Activity Timeline
Record date: May 3, 2025
Publish date: June 30, 2025
Retire date: April 17, 2026

SCAI's Independent Content

As a provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME), it is the Society’s policy to ensure balance, independence, objectivity, and scientific rigor in all its activities.

Planning Process 
SCAI activities are developed by the SCAI planners prior to and independent of commercial support. Members of the Program Committee reviewed and approved this activity. If planners had relevant financial relationships, the agenda was peer reviewed by a member with no relevant financial relationships.

Mitigation of Relevant Financial Relationships
All participating planners, reviewers, faculty, and staff are required to disclose to SCAI all financial relationships with ineligible companies. SCAI identifies relevant financial relationships and mitigates them before the activity begins. 

Content Validation Statement
SCAI accepts the following Content Validation Statements and expects all persons involved in its professional education activities to abide by these statements for clinical care recommendations.

All clinical and pharmacological recommendations are based on evidence accepted within the medical profession as adequate jurisdiction for their indications and contradictions in patient care. SCAI does not promote recommendations, treatment, or manners of practicing medicine that are not within the definition of accredited continuing education or known to have risks or dangers that outweigh the benefits or known to be ineffective in the treatment of patients.

All research referenced to support or justify patient care recommendations conforms to accepted standards of experimental design, data collection and analysis. 

SCAI actively promotes improvements in health care and NOT proprietary interests of an ineligible company. SCAI's educational content is free of marketing or sales of products or services.

Faculty will not actively promote or sell products or services that serve their professional or financial interests during accredited education. 

SCAI encourages faculty to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration (FDA), at first mention and where appropriate in the content.

Copyright
© 2025 Society for Cardiovascular Angiography and Interventions (SCAI). All rights reserved.
Summary
Availability:
On-Demand
Access expires on Apr 17, 2026
Cost:
FREE
Credit Offered:
1 CME Credit
1 ABIM-MOC Point
1 Participation Credit
Powered By